Publication | Closed Access

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

MedicineImmunologyPathologyCancer TreatmentOncologyRadiation OncologyPhase 1Cancer GrowthMetastatic Solid Tumours